Back
Day One Biopharmaceuticals, Inc. 10K Form
Sell
20
DAWN
Day One Biopharmaceuticals, Inc.
Last Price:
$10.03
Seasonality Move:
-34.56%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive DAWN News And Ratings
See the #1 stock for the next 7 days that we like better than DAWN
DAWN Financial Statistics
Sales & Book Value
| Annual Sales: | $158.2M |
|---|---|
| Cash Flow: | $-14.1M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $4.28 |
| Price / Book: | 2.41 |
Profitability
| EPS (TTM): | -1.04210 |
|---|---|
| Net Income (TTM): | $-107.3M |
| Gross Margin: | $141M |
| Return on Equity: | -22.98% |
| Return on Assets: | -20.19% |
Day One Biopharmaceuticals, Inc. Earnings Forecast
Key Day One Biopharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 7 years for DAWN is 89.12%.
-
The Selling, General & Administrative Expenses for DAWN have been equal to 76.23% of Gross Profit Margin.
-
The Research & Development expenses have been 93.65% of Revenue.
-
The Net Earning history of DAWN is -67.85% of Total Revenues.
-
Per Share Earnings over the last 7 years have been positive in 2 years.
Day One Biopharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | DAWN |
| Website: | dayonebio.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 8.02 |
| Quick Ratio: | 7.73 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 556.33 |
DAWN Technical Analysis vs Fundamental Analysis
Sell
20
Day One Biopharmaceuticals, Inc. (DAWN)
is a Sell
Is Day One Biopharmaceuticals, Inc. a Buy or a Sell?
-
Day One Biopharmaceuticals, Inc. stock is rated a SellThe current Day One Biopharmaceuticals, Inc. [DAWN] share price is $10.37. The Score for DAWN is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.